Literature DB >> 28649032

A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18.

Hongliang Chen1, Kejin Wu2, Maoli Wang1, Fuwen Wang1, Mingdi Zhang1, Peng Zhang1.   

Abstract

BACKGROUND: Standard mastectomy has long been the recommended breast surgical treatment for non-metastatic inflammatory breast cancer (IBC). The objective of this population-based study was to evaluate the significance of various breast surgical treatments for this highly aggressive subtype.
METHODS: The Surveillance, Epidemiology, and End Results program registry was searched to identify women with non-metastatic IBC receiving standard treatment including breast surgery, radiation therapy and chemotherapy diagnosed between 1998 and 2013. Comparisons of the proportions of various breast surgery procedures over the years were performed using Pearson's chi-square test. Breast cancer-specific survival (BCSS) and overall survival (OS) were estimated using the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. Cox models were then fitted to compare the association between various breast surgical procedures and BCSS or OS after adjusting for patient and tumor characteristics.
RESULTS: A total of 3374 cases were identified. Over the years, the proportion of contralateral prophylactic mastectomy (CPM), breast reconstruction and both were increasing. The proportion of implant-based reconstruction was also increasing with no difference in survival compared with other types of reconstruction. There was no statistically significant difference in BCSS or OS among various breast surgery treatments, such as breast conserving surgery, CPM, breast reconstruction and standard unilateral mastectomy.
CONCLUSIONS: Breast surgery is of great significance to the clinical outcome of IBC. Standard mastectomy should not be the only recommended breast surgical treatment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer-specific survival; Breast conserving surgery; Breast reconstruction; Contralateral prophylactic mastectomy; Inflammatory breast cancer; Mastectomy; Overall survival

Mesh:

Year:  2017        PMID: 28649032     DOI: 10.1016/j.breast.2017.06.002

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  9 in total

1.  Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.

Authors:  Takahiro Kogawa; Takeo Fujii; Jimin Wu; Kenichi Harano; Tamer M Fouad; Diane D Liu; Yu Shen; Hiroko Masuda; Savitri Krishnamurthy; Mariana Chavez-MacGregor; Bora Lim; Rashmi K Murthy; Vicente Valero; Debu Tripathy; Naoto T Ueno
Journal:  Oncologist       Date:  2020-01-31

Review 2.  Inflammatory Breast Cancer: a Separate Entity.

Authors:  Jennifer M Rosenbluth; Beth A Overmoyer
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

3.  Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment.

Authors:  Hasan Karanlik; Neslihan Cabioglu; Adela Luciana Oprea; Ilker Ozgur; Naziye Ak; Adnan Aydiner; Semen Onder; Süleyman Bademler; Bahadir M Gulluoglu
Journal:  Breast Care (Basel)       Date:  2020-12-16       Impact factor: 2.268

Review 4.  Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy.

Authors:  Monika Brzezinska; J Michael Dixon
Journal:  Gland Surg       Date:  2018-12

5.  Reconstruction in Women with T4 Breast Cancer after Neoadjuvant Chemotherapy: When Is It Safe?

Authors:  Kate R Pawloski; Andrea V Barrio; Mary L Gemignani; Varadan Sevilimedu; Tiana Le; Joseph Dayan; Monica Morrow; Audree B Tadros
Journal:  J Am Coll Surg       Date:  2021-05-03       Impact factor: 6.532

6.  Developing a Decision-Aid Website for Breast Cancer Surgery: An Action Research Approach.

Authors:  Ling-Ming Tseng; Shuh-Jen Sheu; Yu-Ting Hung; Ching-Fang Wu; Te-Hsin Liang; Shin-Shang Chou; Guan-Liang Chen; Pei-Ni Wu; Guan-Rong Su; Tsuey-Huah Jang; Chang-Yi Liu; Ching-Yen Wang
Journal:  J Med Internet Res       Date:  2019-02-04       Impact factor: 5.428

7.  International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Authors:  Naoto T Ueno; Jose Rodrigo Espinosa Fernandez; Massimo Cristofanilli; Beth Overmoyer; Dan Rea; Fedor Berdichevski; Mohamad El-Shinawi; Jennifer Bellon; Huong T Le-Petross; Anthony Lucci; Gildy Babiera; Sarah M DeSnyder; Mediget Teshome; Edward Chang; Bora Lim; Savitri Krishnamurthy; Michael C Stauder; Simrit Parmar; Mona M Mohamed; Angela Alexander; Vicente Valero; Wendy A Woodward
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

8.  Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study.

Authors:  Zhi-Wen Li; Miao Zhang; Yong-Jing Yang; Zi-Jun Zhou; Yan-Ling Liu; Hang Li; Bo Bao; Jian-Dong Diao; Dun-Wei Wang
Journal:  PeerJ       Date:  2020-02-03       Impact factor: 2.984

9.  Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study.

Authors:  Qin Huang; Teng-Yu Xu; Zhi-Yong Wu
Journal:  Med Sci Monit       Date:  2019-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.